Which has better valuation and earnings, AVTX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalo Therapeutics $60K 16,138.99 -$78.26M -$5.46 N/A Telix Pharmaceuticals $803.79M 4.65 -$7.12M N/A N/A

Is AVTX or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -97.54% -72.42% Telix Pharmaceuticals N/A N/A N/A

Does the media refer more to AVTX or TLX?

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 6 mentions for Telix Pharmaceuticals and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.65 beat Telix Pharmaceuticals' score of 0.54 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNLI or AVTX more profitable?

Denali Therapeutics' return on equity of -52.20% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -52.20% -43.86% Avalo Therapeutics N/A -97.54% -72.42%

Does the media favor DNLI or AVTX?

In the previous week, Denali Therapeutics had 8 more articles in the media than Avalo Therapeutics. MarketBeat recorded 11 mentions for Denali Therapeutics and 3 mentions for Avalo Therapeutics. Denali Therapeutics' average media sentiment score of 0.76 beat Avalo Therapeutics' score of 0.65 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVTX or NAMS?

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 3 mentions for Avalo Therapeutics. NewAmsterdam Pharma's average media sentiment score of 1.01 beat Avalo Therapeutics' score of 0.65 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GPCR or AVTX more profitable?

Structure Therapeutics' return on equity of -24.91% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Avalo Therapeutics N/A -97.54% -72.42%

Does the media favor GPCR or AVTX?

In the previous week, Avalo Therapeutics had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 3 mentions for Avalo Therapeutics and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.61 beat Avalo Therapeutics' score of 0.65 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avalo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CPRX or AVTX?

In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 3 mentions for Avalo Therapeutics. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Avalo Therapeutics' score of 0.65 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Avalo Therapeutics (AVTX) Competitors

$18.42 -0.49 (-2.59%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$18.42 0.00 (0.00%)

As of 07/14/2026 06:05 PM Eastern

Compare

AVTX vs. TLX, DNLI, NAMS, GPCR, and CPRX

Should you buy Avalo Therapeutics stock or one of its competitors? MarketBeat compares Avalo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalo Therapeutics include Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), NewAmsterdam Pharma (NAMS), Structure Therapeutics (GPCR), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Avalo Therapeutics (NASDAQ:AVTX) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Avalo Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

Avalo Therapeutics presently has a consensus target price of $45.80, suggesting a potential upside of 148.64%. Telix Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 90.56%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Telix Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	16,138.99	-$78.26M	-$5.46	N/A
Telix Pharmaceuticals	$803.79M	4.65	-$7.12M	N/A	N/A

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Telix Pharmaceuticals' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 6 mentions for Telix Pharmaceuticals and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.65 beat Telix Pharmaceuticals' score of 0.54 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Avalo Therapeutics beats Telix Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Avalo Therapeutics compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Avalo Therapeutics (NASDAQ:AVTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Denali Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Avalo Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.88	-$512.54M	-$2.88	N/A
Avalo Therapeutics	$60K	16,138.99	-$78.26M	-$5.46	N/A

Denali Therapeutics' return on equity of -52.20% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Avalo Therapeutics	N/A	-97.54%	-72.42%

Denali Therapeutics presently has a consensus price target of $34.75, suggesting a potential upside of 53.42%. Avalo Therapeutics has a consensus price target of $45.80, suggesting a potential upside of 148.64%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Denali Therapeutics had 8 more articles in the media than Avalo Therapeutics. MarketBeat recorded 11 mentions for Denali Therapeutics and 3 mentions for Avalo Therapeutics. Denali Therapeutics' average media sentiment score of 0.76 beat Avalo Therapeutics' score of 0.65 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Denali Therapeutics beats Avalo Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to NewAmsterdam Pharma?

Avalo Therapeutics (NASDAQ:AVTX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 3 mentions for Avalo Therapeutics. NewAmsterdam Pharma's average media sentiment score of 1.01 beat Avalo Therapeutics' score of 0.65 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

Avalo Therapeutics currently has a consensus target price of $45.80, suggesting a potential upside of 148.64%. NewAmsterdam Pharma has a consensus target price of $49.00, suggesting a potential upside of 47.19%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Avalo Therapeutics has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	16,138.99	-$78.26M	-$5.46	N/A
NewAmsterdam Pharma	$22.50M	172.96	-$203.82M	-$1.79	N/A

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Avalo Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summary

NewAmsterdam Pharma beats Avalo Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Avalo Therapeutics compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Avalo Therapeutics (NASDAQ:AVTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, Avalo Therapeutics had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 3 mentions for Avalo Therapeutics and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.61 beat Avalo Therapeutics' score of 0.65 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Avalo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Avalo Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Avalo Therapeutics	$60K	16,138.99	-$78.26M	-$5.46	N/A

Structure Therapeutics has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Structure Therapeutics presently has a consensus price target of $110.55, indicating a potential upside of 118.51%. Avalo Therapeutics has a consensus price target of $45.80, indicating a potential upside of 148.64%. Given Avalo Therapeutics' higher probable upside, analysts plainly believe Avalo Therapeutics is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Structure Therapeutics' return on equity of -24.91% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Avalo Therapeutics	N/A	-97.54%	-72.42%

Summary

Structure Therapeutics beats Avalo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Avalo Therapeutics compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Avalo Therapeutics (NASDAQ:AVTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 3 mentions for Avalo Therapeutics. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Avalo Therapeutics' score of 0.65 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Avalo Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Avalo Therapeutics	N/A	-97.54%	-72.42%

Catalyst Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.55	$214.33M	$1.74	18.10
Avalo Therapeutics	$60K	16,138.99	-$78.26M	-$5.46	N/A

Catalyst Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Avalo Therapeutics has a consensus target price of $45.80, suggesting a potential upside of 148.64%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Catalyst Pharmaceuticals beats Avalo Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Avalo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTX vs. The Competition

Export

Metric	Avalo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$994.02M	$3.02B	$6.86B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	-3.37	18.77	27.01	24.38
Price / Sales	16,138.99	344.35	521.33	91.92
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	4.10	4.20	10.95	6.33
Net Income	-$78.26M	$65.13M	$3.59B	$331.02M
7 Day Performance	-4.11%	-2.63%	-1.45%	-0.33%
1 Month Performance	26.16%	2.14%	2.78%	-1.29%
1 Year Performance	283.75%	23.26%	28.53%	21.30%

Avalo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTX Avalo Therapeutics	2.7849 of 5 stars	$18.42 -2.6%	$45.80 +148.6%	+275.9%	$994.02M	$60K	N/A	40
TLX Telix Pharmaceuticals	4.5737 of 5 stars	$11.74 -3.4%	$21.00 +78.9%	-29.2%	$4.12B	$803.79M	N/A	1,184	News Coverage Gap Down
DNLI Denali Therapeutics	3.2757 of 5 stars	$26.31 +2.2%	$34.25 +30.2%	+54.2%	$4.09B	$330.53M	N/A	430	News Coverage Analyst Forecast
NAMS NewAmsterdam Pharma	3.314 of 5 stars	$36.99 +6.0%	$49.00 +32.5%	+50.2%	$4.08B	$22.50M	N/A	4	News Coverage
GPCR Structure Therapeutics	2.6112 of 5 stars	$56.63 +3.4%	$110.55 +95.2%	+158.5%	$3.89B	N/A	N/A	136	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalo Therapeutics (AVTX) Competitors

AVTX vs. TLX, DNLI, NAMS, GPCR, and CPRX

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Avalo Therapeutics compare to Denali Therapeutics?

Summary

How does Avalo Therapeutics compare to NewAmsterdam Pharma?

Summary

How does Avalo Therapeutics compare to Structure Therapeutics?

Summary

How does Avalo Therapeutics compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalo Therapeutics (AVTX) Competitors

AVTX vs. TLX, DNLI, NAMS, GPCR, and CPRX

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Which has more risk & volatility, AVTX or TLX?

Do analysts rate AVTX or TLX?

Which has better valuation and earnings, AVTX or TLX?

Do institutionals and insiders hold more shares of AVTX or TLX?

Is AVTX or TLX more profitable?

Does the media refer more to AVTX or TLX?

Summary

How does Avalo Therapeutics compare to Denali Therapeutics?

Which has more volatility and risk, DNLI or AVTX?

Do insiders and institutionals hold more shares of DNLI or AVTX?

Which has better valuation & earnings, DNLI or AVTX?

Is DNLI or AVTX more profitable?

Do analysts prefer DNLI or AVTX?

Does the media favor DNLI or AVTX?

Summary

How does Avalo Therapeutics compare to NewAmsterdam Pharma?

Does the media prefer AVTX or NAMS?

Which has more risk & volatility, AVTX or NAMS?

Do analysts prefer AVTX or NAMS?

Which has stronger valuation and earnings, AVTX or NAMS?

Do insiders & institutionals hold more shares of AVTX or NAMS?

Is AVTX or NAMS more profitable?

Summary

How does Avalo Therapeutics compare to Structure Therapeutics?

Does the media favor GPCR or AVTX?

Do institutionals & insiders have more ownership in GPCR or AVTX?

Which has preferable earnings & valuation, GPCR or AVTX?

Which has more risk & volatility, GPCR or AVTX?

Do analysts prefer GPCR or AVTX?

Is GPCR or AVTX more profitable?

Summary

How does Avalo Therapeutics compare to Catalyst Pharmaceuticals?

Does the media favor CPRX or AVTX?

Is CPRX or AVTX more profitable?

Which has better valuation & earnings, CPRX or AVTX?

Which has more volatility and risk, CPRX or AVTX?

Do analysts rate CPRX or AVTX?

Do institutionals & insiders believe in CPRX or AVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools